Immuno-Oncology
September 26 - 27, 2018 - London UKSMi Group
LDurneva@smi-online.co.uk
Phone:+4402078276000
At the SMi's Immuno-Oncology Conference participants will get: Agenda - Valuable time is spent to discover the latest trends and hottest topics in the industry to provide the best possible agenda for attendees. 15+ engaging presentations/case studies/keynote addresses, including: - Targeting immune checkpoints with Humabody VH therapeutics - Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy - Tumour mutation burden and the potential of its use as an indication of treatment choice - Unwanted immunogenicity and functionality testing of immuno-oncology drugs - New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology Speakers - Top representation of industry leaders. 15+ leading experts in Immuno-Oncology field, including - James Legg, Vice President R&D, Crescendo Biologics - Andrew Exley, Medical Assessor, MHRA - Harry Smith, Medical Scientist, Gilead Sciences - Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune - David Giljohan, CEO, Exicure - Kandeepan Ganeshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD - Rochana Wickramasinghe, Director of Oncology Evaluation, AstraZeneca Workshops - Carefully selected topics for further on-sight training. 2 pre-conference workshops to provide in-depth knowledge on specific topics: - Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures - Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University Networking - it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.